当前位置: 首页 > 详情页

The Epidemiology of Herpes Zoster and Postherpetic Neuralgia in China: Results from a Cross-Sectional Study.

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Neurology, Chinese PLA General Hospital, Hai Dian District, Beijing, China [2]Department of Pain Medicine, Pain Management Center, China-Japan Friendship Hospital, Chao Yang District, Beijing, China [3]Pain Department Center, Beijing Tian Tan Hospital, Dong Cheng District, Beijing, China [4]Pfizer China, Beijing, China [5]Kantar Health, New York, NY, USA [6]Pfizer Inc, New York, NY, USA [7]Pfizer Inc, Groton, CT, USA [8]Capital Medical University, Beijing, China
出处:
ISSN:

摘要:
Few studies have examined the epidemiology of herpes zoster (HZ) and postherpetic neuralgia (PHN) in China. The aim of this study was to estimate the prevalence of HZ and PHN in China, and to examine the clinical characteristics of patients identified with PHN. This was a cross-sectional study conducted in 24 hospitals in seven cities in China. Prevalence of HZ and PHN was determined by physician (n = 100) chart review of patients (n = 36,170) aged ≥ 40 years seeking medical care over a 30- to 60-day period. The health history of patients identified with PHN was obtained and included time since diagnosis of HZ or PHN, time since onset of PHN-related pain, and the methods used for diagnosing HZ and PHN. The prevalence rates of HZ and PHN were 7.7% [95% confidence interval (CI) 7.5-8.0] and 2.3% (95% CI 2.2-2.5), respectively. Of patients with HZ, 29.8% developed PHN. Rates of HZ and PHN increased with age and were highest in patients aged ≥ 70 years (10.6% and 4.1%, respectively). The majority of patients with PHN were diagnosed with HZ (80.9%) and PHN (83.8%) for < 1 year, and had experienced PHN-related pain for < 1 year (80.5%). Patient description and clinical examination were most commonly used to diagnose HZ and PHN. These results provide current estimates of the prevalence of HZ and PHN in the general adult population in urban China. These rates are similar to previously reported rates in China and worldwide, and highlight the global nature of HZ and PHN. Pfizer Inc.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 临床神经病学
JCR分区:
出版当年[2017]版:
最新[2023]版:
Q1 CLINICAL NEUROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版]

第一作者:
第一作者机构: [1]Department of Neurology, Chinese PLA General Hospital, Hai Dian District, Beijing, China
通讯作者:
通讯机构: [1]Department of Neurology, Chinese PLA General Hospital, Hai Dian District, Beijing, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院